Ceramide-Infused Skin Barrier Cuts Stoma-Related CostsLast Updated: January 12, 2018. Use of a ceramide-infused ostomy skin barrier is associated with reduced stoma-related cost of care, according to a study published in the January/February issue of the Journal of Wound, Ostomy and Continence Nursing.
FRIDAY, Jan. 12, 2018 (HealthDay News) -- Use of a ceramide-infused ostomy skin barrier is associated with reduced stoma-related cost of care, according to a study published in the January/February issue of the Journal of Wound, Ostomy and Continence Nursing.
Janice C. Colwell, R.N., from the University of Chicago Medicine, and colleagues conducted a multicentered international trial involving 153 adults from 25 sites in the United States, Canada, and Europe. Ostomy-related costs were examined and the incidence of peristomal skin complications (PSCs) was compared for ceramide-infused ostomy skin barriers and control skin barriers.
The researchers found that over a 12-week period there was a significant reduction in stoma-related cost of care with use of the ceramide-infused barrier, resulting in a 14 percent relative decrease in cost (reduction of $36.46). The adjusted average costs were $223.73 and $260.19 in the treatment and control groups, respectively (P = 0.017). The overall incidence of PSC was 47.7 percent; 40.5 and 55.4 percent for the control and treatment groups, respectively (P = 0.069; 95 percent confidence interval of the difference, −1.2 to 30.4). In the ceramide-infused skin barrier group, significantly more participants were very satisfied with barrier performance, prevention of leakage, and prevention of itching. Both groups had general postoperative improvement in health-related quality of life.
"The use of a ceramide-infused barrier significantly decreased cost and increased satisfaction with patient-reported outcomes," the authors write.
Several authors disclosed financial ties to medical product companies, including Hollister Incorporated, which funded the study.
|Previous: Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages||Next: FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation|
Reader comments on this article are listed below. Review our comments policy.